BIOMAT Database Logo BIOMAT Database Logo

[In vitro combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa. In vitro synergistic activities]. 1985

Y Iyama, and K Sato, and R Okachi

In vitro synergistic activities of astromicin (ASTM), a new aminoglycoside antibiotic, combined with beta-lactam antibiotics (cefsulodin (CFS), cefoperazone (CPZ), latamoxef (LMOX) were investigated against P. aeruginosa by the checkerboard technique, FIC index and the killing curve. FIC indexes of ASTM in combination with beta-lactam antibiotics against 11 fresh clinical isolates of P. aeruginosa, P. aeruginosa BMH No. 1 and E-2 were synergistic or partially synergistic in most cases. Checkerboard of P. aeruginosa BMH No. 1 and E-2 to ASTM and 3 beta-lactam antibiotics showed the synergism, too. Bacteriostatic concentrations of ASTM, CFS, CPZ or LMOX showed synergistically bactericidal effects when these antibiotics were added in combination to the culture of P. aeruginosa BMH No. 1.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams

Related Publications

Y Iyama, and K Sato, and R Okachi
[In vivo combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa].
June 1986, The Japanese journal of antibiotics,
Y Iyama, and K Sato, and R Okachi
Synergistic activity of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo.
December 1984, The Journal of antibiotics,
Y Iyama, and K Sato, and R Okachi
[In vitro combination effects of astromicin and beta-lactam antibiotics against CFS-sensitive and CFS-resistant Pseudomonas aeruginosa. In vitro synergistic activity].
May 1988, The Japanese journal of antibiotics,
Y Iyama, and K Sato, and R Okachi
Synergistic activities of fortimicin A and beta-lactam antibiotics against Pseudomonas aeruginosa.
July 1981, Antimicrobial agents and chemotherapy,
Y Iyama, and K Sato, and R Okachi
[Synergistic activity of isepamicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo].
November 1988, The Japanese journal of antibiotics,
Y Iyama, and K Sato, and R Okachi
Comparative antibacterial activities of new beta-lactam antibiotics against Pseudomonas aeruginosa.
January 1985, Chemotherapy,
Y Iyama, and K Sato, and R Okachi
beta-Lactamases of Pseudomonas aeruginosa and susceptibility against beta-lactam antibiotics.
February 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Y Iyama, and K Sato, and R Okachi
Comprehensive evaluation of ciprofloxacin in combination with beta-lactam antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa.
February 1986, Arzneimittel-Forschung,
Y Iyama, and K Sato, and R Okachi
Comparative in vitro activity of aztreonam, other beta-lactam antibiotics and aminoglycosides against Pseudomonas aeruginosa.
August 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Y Iyama, and K Sato, and R Okachi
In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa.
May 2021, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!